Primary tabs

Needle-Free Delivery of Stable, Respirable Powder Vaccine

Many serious infections, such as the measles virus, can enter the body through inhalation. Vaccine delivery systems that can target respiratory mucosal tissue and stimulate immune response there have the potential to be particularly effective against these types of infections. Collaborating with an international group that includes the Serum Institute of India (SII), the U.S. Centers for Disease Control and Prevention (CDC), the University of Colorado, and private companies, Dr. Sievers and his colleagues at Aktiv-Dry, LLC (AD) are developing a dry-powder version of the measles vaccine that can be inhaled through a disposable plastic device. Sievers (Grand Challenges in Global Health: 2005-2015 retrospective)

Grant ID
1077 SIEVER05GCGH0
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
19500000.00
Funding Currency
USD
Funding Amount (in USD)
19500000.00
Project Primary Sector
Funding Date Range
-
Funding Total (In US dollars)
19500000.00
Co-Funded
False